Exemple de utilizare a Fluvoxamine în Engleză și traducerile lor în Română
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Programming
Fluvoxamine and inhibitors of CYP1A2.
Antidepressants, such as Fluvoxamine.
Fluvoxamine, used to treat depression;
The tested dose of fluvoxamine was 50 mg.
These include Fluoxetine, Paroxetine,Sertraline and Fluvoxamine.
Concomitant use of fluvoxamine(see section 4.5).
It includes a substance such as fluvoxamine.
Strong CYP1A2 inhibitors(e.g. fluvoxamine, ciprofloxacin and enoxacin).
Fluvoxamine, a specific CYP 1A2 inhibitor, has been shown to significantly inhibit the metabolism of olanzapine.
Strong CYP2C19 inhibitors(e.g. omeprazole, fluvoxamine and moclobemide).
Fluoxetine, fluvoxamine, or moclobemide, medicines to treat depression.
If you take medicines containing fluoxetine, fluvoxamine, dextromethorphan or.
Paroxetine, fluoxetine, fluvoxamine, duloxetine, bupropion, moclobemide- antidepressants(used to treat depression).
Interactions with potent CYP 1A2 inhibitors(e. g. fluvoxamine, ciprofloxacin).
The full therapeutic dose of fluvoxamine would be expected to produce a greater increase in asenapine plasma concentrations.
Concomitant use of potent CYP1A2 inhibitors(e.g. fluvoxamine, ciprofloxacin)(see section 4.5).
Ome antibiotics(for example ciprofloxacin, enoxacin)certain antidepressants such as fluvoxamine.
Therefore, co-administration of asenapine and fluvoxamine should be approached with caution.
At least 14 days shouldelapse between discontinuation of rasagiline and initiation of treatment with fluoxetine or fluvoxamine.
If you are starting treatment with fluoxetine or fluvoxamine, you should wait at least 14 days after stopping AZILECT treatment.
Except for fluvoxamine, none of the interacting medicinal products resulted in clinically relevant alterations in asenapine pharmacokinetics.
Amitriptyline, citalopram, clomipramine, dosulepin, doxepin,fluoxetine, fluvoxamine, imipramine, lofepramine, paroxetine, and sertraline.
Fluvoxamine(100 mg once daily), a potent inhibitor of CYP1A2, decreased the apparent plasma clearance of duloxetine by about 77% and increased AUC0-t 6-fold.
A lower starting dose of olanzapine should be considered in patients who are using fluvoxamine or any other CYP1A2 inhibitors, such as ciprofloxacin.
Fluvoxamine(100 mg once daily), a potent inhibitor of CYP1A2, decreased the apparent plasma clearance of duloxetine by about 77% and increased AUCo-t 6-fold.
Concomitant use of CYP1A2 inhibitors(e.g. fluvoxamine, ciprofloxacin, enoxacin, propranolol and refecoxib) should be avoided, if possible.
Fluvoxamine should be discontinued prior to the initiation of Esbriet therapy and avoided during Esbriet therapy due to the reduced clearance of pirfenidone.
Caution should be used with weak CYP3A inhibitors(e.g. amlopidine,cilostazol, fluvoxamine, goldenseal, isoniazid, ranitidine, ranolazine) in PMs.
An example is fluvoxamine, which is used to treat depression and obsessive compulsive disorder(OCD). medicines known to reduce the activity of an enzyme called‘CYP3A4'.
Yentreve should not be used with monoamine oxidase inhibitors(a group of antidepressants), fluvoxamine(another antidepressant), or ciprofloxacin or enoxacin(types of antibiotic).